People
George Chen left AstraZeneca after seven years to pursue his own line of oncology and immunology R&D.
Warren Buffett, one of America’s best-known investors, is backing multiple pharmaceutical companies developing therapies aimed at curbing the ongoing global COVID-19 pandemic.
Only about one in seven cancer patients today benefit from immunotherapy. OncoMyx aims to increase this number, using a new multi-armed, systemically administered and targeted oncolytic virus.
The 2020 Virtual Texas Life Science Forum, sponsored by BioHouston November 10-12, showcased dozens of innovative, early stage companies seeking partners to reach the next level.
Travere Therapeutics will also begin trading under the new ticker symbol, “TVTX” on the Nasdaq Global Select Market beginning on Nov. 19.
The BioNTech scientist said his vaccine can “bash the virus over the head”.
There have been some concerns over the accuracy of COVID-19 rapid antigen tests—the clinical diagnostic tests that evaluate for active infections by testing for the presence of the virus’s antigens.
A recent study found that Vitamin D deficiency may be associated with an increased COVID-19 risk.
A study recently conducted at Mayo Clinic showed that dysfunctional Tissue Resident Memory (TRM) CD8 T cells are actually working against the elderly, reducing immunity and enabling residual chronic lung issues after respiratory infections such as COVID-19.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
PRESS RELEASES